Reappraisal of GIP Pharmacology for Metabolic Diseases

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Standard

Reappraisal of GIP Pharmacology for Metabolic Diseases. / Finan, Brian; Müller, Timo D; Clemmensen, Christoffer; Perez-Tilve, Diego; DiMarchi, Richard D; Tschöp, Matthias H.

I: Trends in Molecular Medicine, Bind 22, Nr. 5, 05.2016, s. 359-76.

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Harvard

Finan, B, Müller, TD, Clemmensen, C, Perez-Tilve, D, DiMarchi, RD & Tschöp, MH 2016, 'Reappraisal of GIP Pharmacology for Metabolic Diseases', Trends in Molecular Medicine, bind 22, nr. 5, s. 359-76. https://doi.org/10.1016/j.molmed.2016.03.005

APA

Finan, B., Müller, T. D., Clemmensen, C., Perez-Tilve, D., DiMarchi, R. D., & Tschöp, M. H. (2016). Reappraisal of GIP Pharmacology for Metabolic Diseases. Trends in Molecular Medicine, 22(5), 359-76. https://doi.org/10.1016/j.molmed.2016.03.005

Vancouver

Finan B, Müller TD, Clemmensen C, Perez-Tilve D, DiMarchi RD, Tschöp MH. Reappraisal of GIP Pharmacology for Metabolic Diseases. Trends in Molecular Medicine. 2016 maj;22(5):359-76. https://doi.org/10.1016/j.molmed.2016.03.005

Author

Finan, Brian ; Müller, Timo D ; Clemmensen, Christoffer ; Perez-Tilve, Diego ; DiMarchi, Richard D ; Tschöp, Matthias H. / Reappraisal of GIP Pharmacology for Metabolic Diseases. I: Trends in Molecular Medicine. 2016 ; Bind 22, Nr. 5. s. 359-76.

Bibtex

@article{c0565743098644b2b82f3b4001b3fa1f,

title = "Reappraisal of GIP Pharmacology for Metabolic Diseases",

abstract = "Glucagon-like peptide-1 (GLP-1) analogs are considered the best current medicines for type 2 diabetes (T2D) and obesity due to their actions in lowering blood glucose and body weight. Despite similarities to GLP-1, glucose-dependent insulinotropic polypeptide (GIP) has not been extensively pursued as a medical treatment for T2D. This is largely based on observations of diminished responses of GIP to lower blood glucose in select patients, as well as evidence from rodent knockout models implying that GIP promotes obesity. These findings have prompted the belief in some, that inhibiting GIP action might be beneficial for metabolic diseases. However, a growing body of new evidence - including data based on refined genetically modified models and improved pharmacological agents - suggests a paradigm shift on how the GIP system should be manipulated for metabolic benefits.",

keywords = "Animals, Blood Glucose, Diabetes Mellitus, Type 2, Gastric Inhibitory Polypeptide, Glucagon-Like Peptide 1, Humans, Insulin, Metabolic Diseases, Mice, Obesity, Receptors, Gastrointestinal Hormone, Journal Article, Review",

author = "Brian Finan and M{\"u}ller, {Timo D} and Christoffer Clemmensen and Diego Perez-Tilve and DiMarchi, {Richard D} and Tsch{\"o}p, {Matthias H}",

year = "2016",

month = may,

doi = "10.1016/j.molmed.2016.03.005",

language = "English",

volume = "22",

pages = "359--76",

journal = "Trends in Molecular Medicine",

issn = "1471-4914",

publisher = "Elsevier Ltd. * Trends Journals",

number = "5",

}

RIS

TY - JOUR

T1 - Reappraisal of GIP Pharmacology for Metabolic Diseases

AU - Finan, Brian

AU - Müller, Timo D

AU - Clemmensen, Christoffer

AU - Perez-Tilve, Diego

AU - DiMarchi, Richard D

AU - Tschöp, Matthias H

PY - 2016/5

Y1 - 2016/5

N2 - Glucagon-like peptide-1 (GLP-1) analogs are considered the best current medicines for type 2 diabetes (T2D) and obesity due to their actions in lowering blood glucose and body weight. Despite similarities to GLP-1, glucose-dependent insulinotropic polypeptide (GIP) has not been extensively pursued as a medical treatment for T2D. This is largely based on observations of diminished responses of GIP to lower blood glucose in select patients, as well as evidence from rodent knockout models implying that GIP promotes obesity. These findings have prompted the belief in some, that inhibiting GIP action might be beneficial for metabolic diseases. However, a growing body of new evidence - including data based on refined genetically modified models and improved pharmacological agents - suggests a paradigm shift on how the GIP system should be manipulated for metabolic benefits.

AB - Glucagon-like peptide-1 (GLP-1) analogs are considered the best current medicines for type 2 diabetes (T2D) and obesity due to their actions in lowering blood glucose and body weight. Despite similarities to GLP-1, glucose-dependent insulinotropic polypeptide (GIP) has not been extensively pursued as a medical treatment for T2D. This is largely based on observations of diminished responses of GIP to lower blood glucose in select patients, as well as evidence from rodent knockout models implying that GIP promotes obesity. These findings have prompted the belief in some, that inhibiting GIP action might be beneficial for metabolic diseases. However, a growing body of new evidence - including data based on refined genetically modified models and improved pharmacological agents - suggests a paradigm shift on how the GIP system should be manipulated for metabolic benefits.

KW - Animals

KW - Blood Glucose

KW - Diabetes Mellitus, Type 2

KW - Gastric Inhibitory Polypeptide

KW - Glucagon-Like Peptide 1

KW - Humans

KW - Insulin

KW - Metabolic Diseases

KW - Mice

KW - Obesity

KW - Receptors, Gastrointestinal Hormone

KW - Journal Article

KW - Review

U2 - 10.1016/j.molmed.2016.03.005

DO - 10.1016/j.molmed.2016.03.005

M3 - Review

C2 - 27038883

VL - 22

SP - 359

EP - 376

JO - Trends in Molecular Medicine

JF - Trends in Molecular Medicine

SN - 1471-4914

IS - 5

ER -

ID: 186640138